Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Cipla had a narrow range and a breakout from that range, which itself justifies buying. It is part of the pharmaceutical sector. It has already gone through a deep correction. It is well poised for a rally."
The company's trailing 12-month (TTM) EPS was at Rs 17.18 per share. (Dec, 2013). The stock's price-to-earnings (P/E) ratio was 22.37. The latest book value of the company is Rs 110.47 per share. At current value, the price-to-book value of the company was 3.48. The dividend yield of the company was 0.52 percent.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
